These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 28254865)

  • 1. Prospective Evaluation of the Clinical Implications of the Tumor Metabolism and Chemotherapy-Related Changes in Advanced Biliary Tract Cancer.
    Jo J; Kwon HW; Park S; Oh DY; Cheon GJ; Bang YJ
    J Nucl Med; 2017 Aug; 58(8):1255-1261. PubMed ID: 28254865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic Characteristics of Advanced Biliary Tract Cancer Using 18F-Fluorodeoxyglucose Positron Emission Tomography and Their Clinical Implications.
    Cho KM; Oh DY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ
    Oncologist; 2015 Aug; 20(8):926-33. PubMed ID: 26099746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective Evaluation of Changes in Tumor Size and Tumor Metabolism in Patients with Advanced Gastric Cancer Undergoing Chemotherapy: Association and Clinical Implication.
    Park S; Ha S; Kwon HW; Kim WH; Kim TY; Oh DY; Cheon GJ; Bang YJ
    J Nucl Med; 2017 Jun; 58(6):899-904. PubMed ID: 28572288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic and predictive value of metabolic tumor volume on (18)F-FDG PET/CT in advanced biliary tract cancer treated with gemcitabine/oxaliplatin with or without erlotinib.
    Choi MK; Choi JY; Lee J; Heo JS; Choi SH; Choi DW; Lee KT; Lee JK; Lee KH; Park JO; Park YS; Lim HY
    Med Oncol; 2014 Jul; 31(7):23. PubMed ID: 24909509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of 18F-FDG PET-CT as a prognostic marker in advanced biliary tract cancer.
    Braghiroli MI; Mota JM; Duarte PS; Morita TO; Bariani GM; Nebuloni D; Buchpiguel CA; Hoff PM; Riechelmann RP
    Nucl Med Commun; 2018 Mar; 39(3):252-259. PubMed ID: 29381586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of maximum standardized uptake value measured by pretreatment 18F-FDG PET/CT in locally advanced head and neck squamous cell carcinoma.
    Cacicedo J; Fernandez I; Del Hoyo O; Navarro A; Gomez-Iturriaga A; Pijoan JI; Martinez-Indart L; Escudero J; Gomez-Suarez J; de Zarate RO; Perez JF; Bilbao P; Rades D
    Clin Transl Oncol; 2017 Nov; 19(11):1337-1349. PubMed ID: 28540535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Measuring treatment response to systemic therapy and predicting outcome in biliary tract cancer: comparing tumor size, volume, density, and metabolism.
    Sahani DV; Hayano K; Galluzzo A; Zhu AX
    AJR Am J Roentgenol; 2015 Apr; 204(4):776-81. PubMed ID: 25794066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer.
    Cho KM; Park H; Oh DY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ
    Oncotarget; 2017 Jan; 8(2):2329-2341. PubMed ID: 27911876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study.
    Zhu AX; Meyerhardt JA; Blaszkowsky LS; Kambadakone AR; Muzikansky A; Zheng H; Clark JW; Abrams TA; Chan JA; Enzinger PC; Bhargava P; Kwak EL; Allen JN; Jain SR; Stuart K; Horgan K; Sheehan S; Fuchs CS; Ryan DP; Sahani DV
    Lancet Oncol; 2010 Jan; 11(1):48-54. PubMed ID: 19932054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated tumor-to-liver uptake ratio (TLR) from
    Huang J; Huang L; Zhou J; Duan Y; Zhang Z; Wang X; Huang P; Tan S; Hu P; Wang J; Huang M
    Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1958-1968. PubMed ID: 28812134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive Role of Temporal Changes in Intratumoral Metabolic Heterogeneity During Palliative Chemotherapy in Patients with Advanced Pancreatic Cancer: A Prospective Cohort Study.
    Yoo SH; Kang SY; Cheon GJ; Oh DY; Bang YJ
    J Nucl Med; 2020 Jan; 61(1):33-39. PubMed ID: 31201247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of FOLFIRINOX Chemotherapy with Other Regimens in Patients with Biliary Tract Cancers: a Retrospective Study.
    Kus T; Aktas G; Kalender ME; Sevinc A; Camci C
    J Gastrointest Cancer; 2017 Jun; 48(2):170-175. PubMed ID: 27714651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients with recurrent biliary tract cancer have a better prognosis than those with unresectable disease: retrospective analysis of a multi-institutional experience with patients of advanced biliary tract cancer who received palliative chemotherapy.
    Ikezawa K; Kanai M; Ajiki T; Tsukamoto T; Toyokawa H; Terajima H; Furuyama H; Nagano H; Ikai I; Kuroda N; Awane M; Ochiai T; Takemura S; Miyamoto A; Kume M; Ogawa M; Takeda Y; Taira K; Ioka T
    J Hepatobiliary Pancreat Sci; 2014 Feb; 21(2):98-104. PubMed ID: 23798367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complete Metabolic Response on Interim
    Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
    Oncologist; 2017 May; 22(5):526-534. PubMed ID: 28377466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic value of SUV
    Diao W; Tian F; Jia Z
    Eur J Radiol; 2018 Aug; 105():1-7. PubMed ID: 30017264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy.
    Lee DW; Im SA; Kim YJ; Yang Y; Rhee J; Na II; Lee KH; Kim TY; Han SW; Choi IS; Oh DY; Kim JH; Kim TY; Bang YJ
    Cancer Res Treat; 2017 Jul; 49(3):807-815. PubMed ID: 28111425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second-line chemotherapy in patients with advanced or recurrent biliary tract cancer: a single center, retrospective analysis of 294 cases.
    Takahara N; Nakai Y; Isayama H; Sasaki T; Saito K; Oyama H; Kanai S; Suzuki T; Sato T; Hakuta R; Ishigaki K; Takeda T; Saito T; Mizuno S; Kogure H; Tada M; Koike K
    Invest New Drugs; 2018 Dec; 36(6):1093-1102. PubMed ID: 30324343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic immunohistochemical biomarkers of chemotherapy efficacy in biliary tract cancer: A systematic review and meta-analysis.
    Belkouz A; Labeur TA; Dierks J; Dijk F; van Oijen MGH; Verheij J; van Gulik TM; van de Vijver MJ; Wilmink H; Punt CJA; Klümpen HJ
    Crit Rev Oncol Hematol; 2019 Sep; 141():82-94. PubMed ID: 31255992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CA19-9 kinetics during systemic chemotherapy in patients with advanced or recurrent biliary tract cancer.
    Takahara N; Nakai Y; Isayama H; Sasaki T; Saito K; Noguchi K; Suzuki T; Nakamura T; Sato T; Ishigaki K; Hakuta R; Takeda T; Uchino R; Mizuno S; Kogure H; Tada M; Koike K
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1105-1112. PubMed ID: 29038848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The predictive value of
    Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
    Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.